{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:41:12Z","timestamp":1776238872262,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Definitive chemoradiotherapy (dCRT) can achieve durable local control and even cure in patients with locally advanced esophageal cancer. However, survival benefit may be accompanied by a decline in health-related quality of life (HRQoL) owing to experienced adverse effects. This study aims to investigate HRQoL in patients with locally advanced esophageal cancer receiving dCRT in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with locally advanced esophageal squamous cell carcinoma or adenocarcinoma receiving dCRT (\u2265\u200950.4\u00a0Gy\/28 fractions with concomitant weekly chemotherapy) were eligible. Patient-reported outcome measures were prospectively collected using the validated questionnaires EORTC-QLQ-C30 and EORTC-QLQ-OG25 at baseline and every 3\u00a0months thereafter for 2\u00a0years. Clinical data were obtained from the Netherlands Cancer Registry. Longitudinal HRQoL outcomes were compared to baseline using mixed effect models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      318 patients were included with a median age of 70\u00a0years. The total number of available questionnaires across all timepoints was 718. Out of 318 alive patients, 223 (70.1%) returned a questionnaire at baseline, which declined to 71 out of 195 (36.4%) at 2\u00a0years. Global health status at baseline was 70.6 (95% CI 68.1\u201373.1) and remained stable over time. Patients reported significantly lower physical (-13.0), role (-18.9), cognitive (-6.6), and social functioning (-14.4) at 3\u00a0months compared to baseline (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Social and cognitive functioning scores recovered to baseline level at 6\u00a0months. Physical and role functioning, and the symptom scales fatigue and dyspnea, remained impaired until 2\u00a0years after baseline. Significant improvements were observed for anxiety, eating restrictions, odynophagia and dysphagia at nearly all time points, but most pronounced at 12 or 18\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed that where global health status remained stable from 6\u00a0months after dCRT, the burden of disease-specific symptoms decreased. Social and cognitive functioning first deteriorated but recovered over time, whereas the decline in physical functioning, role functioning, fatigue and dyspnea did not recover to baseline level. These findings can provide valuable insights to address concerns regarding the impact of dCRT on HRQoL within the context of shared decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10450-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:42:19Z","timestamp":1773124939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life after definitive chemoradiotherapy in patients with esophageal carcinoma: a population-based analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"D.","family":"Wekking","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. H.","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C.","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S. N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Jeene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. J.","family":"Neelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Loosveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A. G.","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. H. A.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"3","key":"10450_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"9864","key":"10450_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/s0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400\u2013412. https:\/\/doi.org\/10.1016\/s0140-6736(12)60643-6","journal-title":"Lancet"},{"issue":"10","key":"10450_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A et al (2022) Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(10):992\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003","journal-title":"Ann Oncol"},{"issue":"1","key":"10450_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sj.bjc.6601461","volume":"90","author":"TD Crosby","year":"2004","unstructured":"Crosby TD, Brewster AE, Borley A et al (2004) Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90(1):70\u201375. https:\/\/doi.org\/10.1038\/sj.bjc.6601461","journal-title":"Br J Cancer"},{"issue":"25","key":"10450_CR5","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/jco.20.03697","volume":"39","author":"M Hulshof","year":"2021","unstructured":"Hulshof M, Geijsen ED, Rozema T et al (2021) Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol 39(25):2816\u20132824. https:\/\/doi.org\/10.1200\/jco.20.03697","journal-title":"J Clin Oncol"},{"issue":"5","key":"10450_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/dote.12215","volume":"28","author":"E Versteijne","year":"2015","unstructured":"Versteijne E, van Laarhoven HW, van Hooft JE et al (2015) Definitive chemoradiation for patients with inoperable and\/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus 28(5):453\u2013459. https:\/\/doi.org\/10.1111\/dote.12215","journal-title":"Dis Esophagus"},{"issue":"22","key":"10450_CR7","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"issue":"3","key":"10450_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H et al (2023) Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus 20(3):343\u2013372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2","journal-title":"Esophagus"},{"issue":"23","key":"10450_CR9","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/jco.20.00866","volume":"38","author":"MA Shah","year":"2020","unstructured":"Shah MA, Kennedy EB, Catenacci DV et al (2020) Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 38(23):2677\u20132694. https:\/\/doi.org\/10.1200\/jco.20.00866","journal-title":"J Clin Oncol"},{"issue":"15","key":"10450_CR10","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.7150\/jca.44447","volume":"11","author":"L Xiao","year":"2020","unstructured":"Xiao L, Czito BG, Pang Q et al (2020) Do higher radiation doses with concurrent chemotherapy in the definitive treatment of esophageal cancer improve outcomes? A meta-analysis and systematic review. J Cancer 11(15):4605\u20134613. https:\/\/doi.org\/10.7150\/jca.44447","journal-title":"J Cancer"},{"key":"10450_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.radonc.2021.03.031","volume":"159","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Feng W, Gao L-T et al (2021) Long-term follow-up of a phase I\/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma. Radiother Oncol 159:190\u2013196. https:\/\/doi.org\/10.1016\/j.radonc.2021.03.031","journal-title":"Radiother Oncol"},{"issue":"1","key":"10450_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ejcts\/ezw264","volume":"51","author":"B Kidane","year":"2016","unstructured":"Kidane B, Sulman J, Xu W et al (2016) Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status\u2020. Eur J Cardiothorac Surg 51(1):148\u2013154. https:\/\/doi.org\/10.1093\/ejcts\/ezw264","journal-title":"Eur J Cardiothorac Surg"},{"key":"10450_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.05.025","author":"M Pape","year":"2023","unstructured":"Pape M, Veen LM, Smit TM et al (2023) Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10450_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/0284186x.2016.1240880","volume":"56","author":"PM Jeene","year":"2017","unstructured":"Jeene PM, Versteijne E, van Berge Henegouwen MI et al (2017) Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. Acta Oncol 56(1):33\u201338. https:\/\/doi.org\/10.1080\/0284186x.2016.1240880","journal-title":"Acta Oncol"},{"issue":"2","key":"10450_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/0284186X.2017.1346381","volume":"57","author":"RRJ van den Coebergh Braak","year":"2018","unstructured":"van den Coebergh Braak RRJ, van Rijssen LB, van Kleef JJ et al (2018) Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol 57(2):195\u2013202. https:\/\/doi.org\/10.1080\/0284186X.2017.1346381","journal-title":"Acta Oncol"},{"key":"10450_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A (2002) Quality of life research within the EORTC\u2014the EORTC QLQ-C30. Eur J Cancer 38:125\u2013133. https:\/\/doi.org\/10.1016\/S0959-8049(01)00448-8","journal-title":"Eur J Cancer"},{"issue":"14","key":"10450_CR17","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.ejca.2007.07.005","volume":"43","author":"P Lagergren","year":"2007","unstructured":"Lagergren P, Fayers P, Conroy T et al (2007) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago\u2013gastric junction and the stomach. Eur J Cancer 43(14):2066\u20132073. https:\/\/doi.org\/10.1016\/j.ejca.2007.07.005","journal-title":"Eur J Cancer"},{"key":"10450_CR18","unstructured":"Fayers P,\u00a0Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels"},{"issue":"11","key":"10450_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks K, King MT, Velikova G et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713\u20131721. https:\/\/doi.org\/10.1016\/j.ejca.2012.02.059","journal-title":"Eur J Cancer"},{"issue":"1","key":"10450_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","journal-title":"J Clin Oncol"},{"issue":"1","key":"10450_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2023.05.025","volume":"117","author":"M Pape","year":"2023","unstructured":"Pape M, Veen LM, Smit TM et al (2023) Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 117(1):31\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10450_CR22","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s11136-023-03404-2","volume":"32","author":"KM de Ligt","year":"2023","unstructured":"de Ligt KM, Aaronson NK, Liegl G, Nolte S (2023) Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study. Qual Life Res 32(9):2477\u20132487. https:\/\/doi.org\/10.1007\/s11136-023-03404-2","journal-title":"Qual Life Res"},{"issue":"1","key":"10450_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/jjco\/hyt170","volume":"44","author":"H Yamashita","year":"2014","unstructured":"Yamashita H, Omori M, Okuma K, Kobayashi R, Igaki H, Nakagawa K (2014) Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer. Jpn J Clin Oncol 44(1):78\u201384. https:\/\/doi.org\/10.1093\/jjco\/hyt170","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10450_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0b013e3181fcd991","volume":"253","author":"AYB Teoh","year":"2011","unstructured":"Teoh AYB, Yan Chiu PW, Wong TCL, Liu SYW, Hung Wong SK, Ng EKW (2011) Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg 253(1):1\u20135. https:\/\/doi.org\/10.1097\/SLA.0b013e3181fcd991","journal-title":"Ann Surg"},{"issue":"2","key":"10450_CR25","first-page":"45","volume":"4","author":"LA Kachnic","year":"2011","unstructured":"Kachnic LA, Winter K, Wasserman T et al (2011) Longitudinal Quality-of-Life Analysis of RTOG 94\u201305 (Int 0123): A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res 4(2):45\u201352","journal-title":"Gastrointest Cancer Res"},{"key":"10450_CR26","doi-asserted-by":"publisher","unstructured":"Gillham CM, Aherne N, Rowley S, Moore J, Hollywood D, O'Byrne K et al (2008) Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. Clin Oncol (R Coll Radiol) 20(3):227\u2013233.\u00a0https:\/\/doi.org\/10.1016\/j.clon.2007.12.002","DOI":"10.1016\/j.clon.2007.12.002"},{"issue":"8","key":"10450_CR27","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00268-010-0595-0","volume":"34","author":"SH Chou","year":"2010","unstructured":"Chou SH, Li HP, Lee JY, Huang MF, Lee CH, Lee KW (2010) Radical resection or chemoradiotherapy for cervical esophageal cancer? World J Surg 34(8):1832\u20131839","journal-title":"World J Surg"},{"issue":"84","key":"10450_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2017.07.038","volume":"2017","author":"C Bascoul-Mollevi","year":"2017","unstructured":"Bascoul-Mollevi C, Gourgou S, Galais MP et al (2017) Health-related quality of life results from the PRODIGE 5\/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer 2017(84):239\u2013249","journal-title":"Eur J Cancer"},{"issue":"5","key":"10450_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl033","volume":"17","author":"F Bonnetain","year":"2006","unstructured":"Bonnetain F, Bouch\u00e9 O, Michel P et al (2006) A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 17(5):827\u2013834. https:\/\/doi.org\/10.1093\/annonc\/mdl033","journal-title":"Ann Oncol"},{"issue":"4","key":"10450_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/bjc.2015.258","volume":"113","author":"J Rees","year":"2015","unstructured":"Rees J, Hurt CN, Gollins S et al (2015) Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 113(4):603\u2013610","journal-title":"Br J Cancer"},{"key":"10450_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/ncc.0000000000000946","author":"A-S Baudry","year":"2021","unstructured":"Baudry A-S, Gehenne L, Grynberg D et al (2021) Is the postsurgical quality of life of patients with esophageal or gastric cancer influenced by emotional competence and neoadjuvant treatments? Cancer Nurs. https:\/\/doi.org\/10.1097\/ncc.0000000000000946","journal-title":"Cancer Nurs"},{"key":"10450_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cpr.2017.06.003","volume":"56","author":"L Curran","year":"2017","unstructured":"Curran L, Sharpe L, Butow P (2017) Anxiety in the context of cancer: a systematic review and development of an integrated model. Clin Psychol Rev 56:40\u201354. https:\/\/doi.org\/10.1016\/j.cpr.2017.06.003","journal-title":"Clin Psychol Rev"},{"key":"10450_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00877","volume":"9","author":"L Giuranno","year":"2019","unstructured":"Giuranno L, Ient J, De Ruysscher D, Vooijs MA (2019) Radiation-Induced Lung Injury (RILI). Front Oncol 9:877. https:\/\/doi.org\/10.3389\/fonc.2019.00877","journal-title":"Front Oncol"},{"issue":"1","key":"10450_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijrobp.2020.08.055","volume":"109","author":"YD Tseng","year":"2021","unstructured":"Tseng YD, Hoppe BS, Dedeckova K et al (2021) Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed\/refractory lymphoma: a PTCOG and PCG collaboration. Int J Radiat Oncol Biol Phys 109(1):220\u2013230. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.055","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10450_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ejso.2021.08.015","volume":"48","author":"EAE Reijneveld","year":"2022","unstructured":"Reijneveld EAE, Bor P, Dronkers JJ, Argudo N, Ruurda JP, Veenhof C (2022) Impact of curative treatment on the physical fitness of patients with esophageal cancer: a systematic review and meta-analysis. Eur J Surg Oncol 48(2):391\u2013402. https:\/\/doi.org\/10.1016\/j.ejso.2021.08.015","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10450_CR36","doi-asserted-by":"publisher","DOI":"10.2196\/27824","volume":"23","author":"LF van de Water","year":"2021","unstructured":"van de Water LF, van den Boorn HG, Hoxha F et al (2021) Informing patients with esophagogastric cancer about treatment outcomes by using a web-based tool and training: development and evaluation study. J Med Internet Res 23(8):e27824. https:\/\/doi.org\/10.2196\/27824","journal-title":"J Med Internet Res"},{"key":"10450_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jclinepi.2023.10.009","volume":"164","author":"SC Kuijper","year":"2023","unstructured":"Kuijper SC, Besseling J, Klausch T et al (2023) Assessing real-world representativeness of prospective registry cohorts in oncology: insights from patients with esophagogastric cancer. J Clin Epidemiol 164:65\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.10.009","journal-title":"J Clin Epidemiol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10450-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:41:38Z","timestamp":1776235298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10450-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10450"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10450-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"299"}}